IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock.

 IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock. 

IABP-shock-artigo
Holger Thiele
2012-08-26

Original title: IABP-SHOCK II: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock

More articles by this author

ACCESS-EUROPE: 12 months results in percutaneous treatment of mitral insufficiency .

Presentation Summary: ACCESS-EUROPE multicenter registry included 567 patients with severe mitral regurgitation treated with Mitral Clip in 14 European centers. Procedural success was high,...

GRACE: Use of insulin glargine and fatty acids to reduce atherosclerosis progression.

Presentation Summary: There is a clear association between hyperglycemia and the development of atherosclerosis. The GRACE sub trial, (from ORIGIN study), evaluated the administration...

GARY: German Aortic Valve Registry.

Presentation Summary: The German Aortic Stenosis Registry collected data from German centers. 13,860 patients who were undergoing valve replacement surgery or percutaneous valve implant...

FAST MI: AMI improved the survival associated with the clinical characteristics changes of patients in the French National Registry.

Presentation Summary: The French National Registry included patients admitted with acute myocardial infarction between 1995 and 2010 (n = 6707). Over time, authors noted...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....